Steatotic liver disease (SLD), formerly known as fatty liver disease, is associated with increased cancer risk. However, the impact of socioeconomic inequities remains understudied. This study investigates the relationship between SLD, socioeconomic position (SEP) and cancer risk using a syndemic framework.

Sarcoidosis is a rare systemic granulomatous disease involving the liver in up to 20% of cases. Data on hepatic sarcoidosis (HS) prevalence and management remain limited. This study aims to provide a comprehensive analysis of HS patients across Italy, focusing on diagnostic pathways, management strategies, and prognostic factors.

Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality, particularly in patients with advanced stage. Atezolizumab plus bevacizumab (Ate/Bev) is the standard first-line therapy; however, its efficacy may be further enhanced using combination strategies.

Polycystic liver disease (PLD) is a rare genetic disorder characterised by progressive liver enlargement due to multiple cysts. The main symptoms are liver volume-related. Although randomised controlled trials have shown that somatostatin analogues (SSAs) reduce liver volume as well as symptoms, specific guidance on when and how to use SSAs in clinical practice is still lacking. A panel of 15 hepatologists and nephrologists developed practical guidance on SSA use, based on a systematic literature search, expert surveys, and clinical experience. This consensus was reached during a two-day workshop by the European Reference Network on Hepatological Diseases, using 11 predefined key questions and an iterative Delphi process. PLD patients with liver volume-related symptoms, diffuse disease, and significant hepatomegaly are eligible for SSA therapy, regardless of kidney function. Disease burden should be assessed with validated PROMs as well as liver volumetry before and during treatment. Symptom relief without liver growth is a valid treatment response. Therapy may continue until the natural course of disease slows down (e.g., with the onset of menopause). Trials report benefits of SSA therapy for up to 3-4 years. Early discontinuation may cause a rebound of liver volume. As SSA therapy remains off-label, limited access and reimbursement hamper widespread use in Europe. We present state-of-the-art guidance on the practical use of the only available medical therapy for severe PLD including eligibility, start and stop criteria and identifying research gaps. This consensus-based guidance provides much-needed practical recommendations for the use of somatostatin analogues in managing severe polycystic liver disease. By defining eligibility, treatment goals, and monitoring strategies, it supports more standardised, patient-centered care across Europe.

Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child-Pugh class B (CP-B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP-B.

Hepatocellular carcinoma (HCC) development in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern, but the underlying mechanisms are not fully understood. Epigenetic aging biomarkers, reflecting cellular and tissue aging, have been linked to various age-related pathologies, but their association with MASLD-HCC is unknown. We investigated associations between five epigenetic aging biomarkers and MASLD-HCC risk.

Steatotic liver disease (SLD) affects more than 30% of the global population; however, trends in its prevalence remain poorly understood. This study aimed to elucidate prevalence trends of metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with moderate alcohol intake (MetALD), and alcohol-associated liver disease (ALD) in the Japanese general population.

Hypogonadism is frequent in AdvCLD and associated with frailty and poor outcomes. This study aimed to evaluate the association between free testosterone (FT) levels and all-cause mortality in male patients with AdvCLD awaiting liver transplantation (LT), and to compare the prognostic value of FT with total testosterone (TT).